8-K: Akoya Biosciences Stockholders Approve Merger with Quanterix Corporation

Akoya Biosciences, Inc. stockholders overwhelmingly approved the proposed merger with Quanterix Corporation at a special meeting held on July 7, 2025.

Summary

• Akoya Biosciences, Inc. held a special meeting of its stockholders on July 7, 2025.
• Out of 49,954,210 shares of common stock issued and outstanding as of the June 5, 2025 record date, 42,421,181 shares were represented, constituting approximately 85% of outstanding shares and a quorum.
• Stockholders approved Proposal 1, the adoption of the Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and Wellfleet Merger Sub, Inc., dated April 28, 2025, with 42,261,529 votes For, 97,486 Against, and 62,166 Abstentions.
• Stockholders also approved Proposal 2, the proposal to adjourn the Special Meeting if necessary to solicit additional proxies for the merger proposal, with 41,986,179 votes For, 340,995 Against, and 94,007 Abstentions.
• The adjournment of the Special Meeting was not necessary as the Akoya Merger Proposal was approved.

Sentiment

Score: 8

Explanation: The overwhelming approval of the merger by stockholders is a significant positive event, indicating successful progression of a key strategic initiative.

Positives

• The Akoya Merger Proposal was overwhelmingly approved by stockholders, indicating strong support for the strategic transaction.
• A high quorum of approximately 85% of outstanding shares was achieved, demonstrating significant stockholder engagement.

Future Outlook

The approval of the merger agreement by stockholders indicates that the merger with Quanterix Corporation is expected to proceed as planned.

Management Comments

• Brian McKelligon, Chief Executive Officer, signed the report on behalf of Akoya Biosciences, Inc.

Industry Context

The approval of this merger reflects ongoing consolidation and strategic alignment within the life sciences and diagnostics industry, as companies seek to enhance capabilities and market reach through combinations.

Corporate Governance

Stakeholder Impact

• Shareholders have approved a significant strategic transaction, which will result in their shares being exchanged according to the merger agreement terms.
• The merger's progression will impact employees, customers, and suppliers as the two companies integrate operations.

Next Steps

• The company is expected to proceed with the closing of the merger with Quanterix Corporation, following the stockholder approval.

Key Dates

Keywords

Akoya Biosciences, Quanterix Corporation, Merger, Stockholder Vote, Special Meeting, Corporate Action, SEC Filing, 8-K, AKYA